EUCOPE - European Confederation of Pharmaceutical Entrepreneurs

📢 SAVE THE DATE ! Register now for the FTI Consulting EU and #EUCOPE launch event of the report: “The Economic Lens: Understanding what makes the EU attractive for life sciences”!   📊 The report, and the event, explores the European Union's ability to attract #LifeSciences investments and the possible impact of the proposed pharmaceutical package on investor confidence.   📅 14 November 🕒 16:30 – 18:00 CET 🖥️ Zoom   🧭 As global competition in life sciences intensifies, Europe stands at a pivotal crossroads. Policy decisions during the next Commission mandate will be critical in determining the future of the EU, to maintain investments in innovation, as well as maintaining access to innovative treatments for patient.   Small and mid-sized innovative companies are pivotal in driving medical advancements across Europe. The event will explore the report’s key findings and engage in an interactive dialogue on strategies to maintain Europe’s competitiveness.   🎤 Speakers and panellists include: 🔹 MEP Stine Bosse (Renew, Denmark) Vice-Chair of Subcommittee on Public Health (#SANT) - European Parliament 🔹 Antoine Mialhe, Head of Healthcare and Life Sciences - FTI Consulting (moderator) 🔹 Florian Schmidt, Deputy Head of Unit "Medicines: Policy, Authorisation and Monitoring" - DG SANTE, European Commission, 🔹 Raúl Martín-Ruiz, Partner - Ysios Capital, 🔹 Toon Digneffe, Head of Public Affairs & Public Policy Europe & Canada - Takeda, and 🔹 Alexander Natz, Secretary General - EUCOPE. 👉 More information and registration for online participation: https://lnkd.in/eg2HeDnw   #EuropeanCompetitiveness #HealthcareInvestments #EURegulations #PharmaSMEs

🌍 The burden of #rarediseases on patients, their carers and families, healthcare systems, and society overall, merits greater visibility and recognition.   Join Chiesi Deutschland for an immersive and engaging multi-stakeholder discussion on the burden of care for rare diseases and the economic impact on #German citizens.   REGISTER - https://lnkd.in/e3agc6DN 📆Tuesday, 26 November - 16:00 – 18:30 CET 📍 Langenbeck-Virchow-Haus, 5. OG (#Berlin, Germany)   Moderated by Ulrich Tilly, the speakers include: Stefanie N. Falkenburg, Senior Director, Rare Diseases, Germany, Chiesi Group2 Prof. Prof. Sylvia Thun, Charité Mental Health Prof. Dr. Grüters-Kieslich Annette, Eva Luise und Horst Köhler Stiftung Prof. Andrew Ullmann (MdB - FDP) Linda Heitmann (MdB - Bündnis 90/Die Grünen), Erich Irlstorfer (MdB - CDU/CSU)   **Please note that the entire discussion will take place in the German language #RareDiseases #Healthcare #Berlin

📢 Today at 2 PM: EUCOPE joins the #BioEurope2024 Panel Discussion: "Pay The Price": Reimbursement - is there now a single HTA procedure in the European Union?   🎤 EUCOPE's Secretary General, Alexander Natz will participate in the panel discussion on reimbursement and the evolving Health Technology Assessment (HTA) landscape in the European Union.   🧬 🧪 Experts will explore how small and large biopharmaceutical companies need to adapt to the new procedure to reach Europe’s patients quickly and successfully with their innovative therapies.   👉 More information about the event: https://lnkd.in/e5f6v2cG   With the EU HTA implementation approaching in January 2025, it’s essential for small and mid-size pharmaceutical companies to prepare now. Contact EUCOPE's team for guidance and insights to support your pathway to market access in Europe!   #EUCOPE #EUHTA #Biopharma #Innovation #PatientAccess

⏰ DON’T FORGET TO REGISTER!   🔜 With three weeks to go until our annual TRANSFORM MEP Interest Group Conference, we’re excited to share the speaker lineup for our second panel: join MEP Tomislav Sokol, Iva Galovic from the European Federation of Neurological Associations, and Adam Parnaby from Bristol Myers Squibb on 21 November for an insightful panel discussion on the current regulatory and legislative state of play for ATMPs.   🔬Our panelists will share their insight into today’s challenges for ATMP research, development and access, and whether the Pharmaceutical Package and forthcoming HTA Regulation, along with other legislative changes, will succeed in addressing these gaps.   🧪 In-person registrations close next week! Visit our website to check out the agenda and register for the event: https://lnkd.in/e5XfpZRH   #MEPsforATMPs #cellandgenetherapy #raredisease #competitiveness #orphanmedicines #EuropeanParliament

👋 Invitation to join us in Strasbourg! The University of Strasbourg is hosting a high-level conference on “#HealthTechnologyAssessment in Europe: Transformation, Performance” at the European Parliament. 📅 8 November - 🕘 9:00 to 17:30 CET - 📍 in-person event EUCOPE's Secretary General Alexander Natz will join leading figures from European and national HTA bodies as well as socio-economic players including European patients, physicians and entrepreneurs organizations, for direct, convivial, fruitful interactions. Don’t miss this chance to engage in a forward-looking discussion shaping the future of European in healthcare. 👉 More details here: https://lnkd.in/ebcZACD5 #HealthTech #HTA #EUHealth #Innovation

Curious about how EU policies are shaping the future of Real-World Evidence (RWE) in Health Technology Assessments (HTA)? Join us at the Annual RWE4Decisions Symposium for an expert panel discussion on “The Policy Context for Real-World Evidence to Support Innovation in HTA”!   Moderated by Francois Meyer, RWE4Decisions Facilitator and Special Advisor at FIPRA Public Affairs, this session will feature insights from key stakeholders, including:   - Patrice Verpillat, Head of Real-World Evidence at the European Medicines Agency, provides an update on the role of DARWIN EU in supporting regulatory and payer decisions. - Enrique Terol, Coordinating Advisor on Health at the Representación Permanente de España en la UE | Permanent Representation of Spain to the EU, presenting the Council’s perspective on current EU health priorities on the EDHS, HTA Regulation, and the revision of the pharmaceutical legislation - Anne-Pierre Pickaert, a Member of the Acute Leukemia Advocates Network, highlights the needs and views of patients in these regulatory shifts. - Alexander Natz, Secretary-General at the EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, shares the industry’s viewpoint on these continuous changes.   Together, we’ll explore critical questions such as: - How will EU initiatives like the European Health Data Space and HTA Regulation affect RWE? - What are the opportunities for collaboration between regulators, HTA payers, and other stakeholders? - How will the DARWIN EU network support innovation?   🔗 Have we sparked your interest? Then don't forget to register here: https://lnkd.in/eYdNXqxT 📅 Date & Time: 14 November, 09:00-13:00 CET 📍 Location: Hybrid - attend in person in Brussels or join online from anywhere   #RWE4Decisions #HTA #EUHealth #RealWorldEvidence #RWE #EHDS

🚀 You're Invited! Join us for the online launch of FTI Consulting EU & EUCOPE’s latest report: “The Economic Lens: Understanding What Makes the EU Attractive for Life Sciences.” 📊 This report examines the EU’s potential to attract life sciences investments and the implications of the proposed pharmaceutical package. With global competition heating up, Europe faces a critical moment to shape its future in life sciences. 🗓 14 November ⏰ 16:30 – 18:00 CET 📍 Online via Zoom 🌍 Small and mid-sized innovative companies are central to Europe’s medical advances. This event will unpack the report’s findings and strategies to enhance Europe’s competitive edge. 🎤 Featured Speakers: 🔹 MEP Stine Bosse – Vice-Chair, Subcommittee on Public Health (SANT), European Parliament 🔹 Florian Schmidt – Deputy Head of Unit "Medicines: Policy, Authorisation and Monitoring," DG SANTE, European Commission 🔹 Raúl Martín-Ruiz – Partner, Ysios Capital 🔹 Toon Digneffe – Head of Public Affairs & Public Policy Europe & Canada, Takeda 🔹 Alexander Natz – Secretary General, EUCOPE 🔹 Antoine Mialhe – Head of Healthcare and Life Sciences, FTI Consulting EU (moderator) 👉 Register now to reserve your spot: https://lnkd.in/eg2HeDnw #EuropeanCompetitiveness #HealthcareInvestments #EURegulations #LifeSciences

🗣️Our call for nominations to join ERDERA Multi-stakeholder Advisory Board is still open. If you have any of the expertise required and want to make a difference in rare disease research, please apply now! ⌛Deadline - 31 October 2024 🔎 https://loom.ly/-fvnkKs European Health and Digital Executive Agency (HaDEA) ANR (Agence nationale de la recherche) Fondazione Telethon Research Council of Lithuania | Lietuvos mokslo taryba EBERHARD-KARLS-UNIVERSITAT TUBINGEN Centro Nacional de Análisis Genómico (CNAG) Vall d’Hebron Institute of Research (VHIR) - Vall d'Hebron Institut de Recerca AP-HP INTERNATIONAL EATRIS EURORDIS-Rare Diseases Europe Fondation Maladies Rares Duchenne Data Foundation FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV

🌟ONE MONTH LEFT! 🔜With less than a month to go until our annual TRANSFORM MEP Interest Group Conference, we’re excited to announce the first speaker line-up: join Matt Bolz-Johnson from EURORDIS-Rare Diseases Europe, MEP Stine Bosse from the European Parliament, and Francis Pang from Orchard Therapeutics - U.S. on 21 November for an insightful panel discussion on the future environment for the development and delivery of ATMPs. 🧬Our panelists will discuss everything biotech, competitiveness and timely access, from the Draghi Report conclusions on barriers to ATMP R&D and patient delivery, to the highly anticipated Biotech Act and broader Strategy for European Life Sciences. 💊 More speaker announcements to follow! Read more about our event and register to join us in-person or online here: https://lnkd.in/e5XfpZRH #MEPsforATMPs #cellandgenetherapy #raredisease #competitiveness #orphanmedicines #EuropeanParliament

🌟 A powerful morning at #WODC2024 as EUCOPE's Governement Affairs Director Victor Maertens joined experts to tackle a pivotal question: How can we build a sustainable and robust pipeline for rare diseases and gene therapies? In this insightful session, rare disease and gene therapy specialists joined forces to discuss key areas shaping the future: 🔬 The transformative potential of gene therapies for future pipelines 🧬 Scientific challenges 📈 Overcoming commercial and post-market evidence hurdles to ensure accessibility 📜 The evolution of regulatory science to keep pace with cutting-edge therapies A warm thank you to Paolo Morgese (Alliance for Regenerative Medicine), Thomas Butt (BioMarin Pharmaceutical Inc.), Francis Pang (Orchard Therapeutics - U.S.) and Daria Julkowska (International Rare Diseases Research Consortium (IRDiRC)) for their valuable perspectives and to #WODC for facilitating this critical conversation. EUCOPE is proud to be part of the ongoing conversations that will drive innovation and support patient needs! 👋 Whether you’re attending in person or online, connect with the EUCOPE team to dive deeper into these critical topics: 🔹 Alexander Natz - EUCOPE Secretary General 🔹 Victor Maertens - EUCOPE Governement Affairs Director 🔹 Stefano Romanelli - EUCOPE Senior Governement Affairs Manager 👉 More information about the event: https://lnkd.in/dkxcGrX #RareDisease #GeneTherapies #EUCOPE #WODC #InnovationInHealthcare #SustainableHealthcare